Amgen Inc. $AMGN Shares Sold by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 67.3% during the third quarter, Holdings Channel reports. The institutional investor owned 985 shares of the medical research company’s stock after selling 2,027 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Amgen were worth $415,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. MW Advisory LLC acquired a new position in Amgen during the 2nd quarter valued at approximately $1,054,000. Baird Financial Group Inc. increased its position in shares of Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the period. Nilsine Partners LLC acquired a new stake in shares of Amgen in the second quarter worth $3,329,000. KBC Group NV lifted its position in Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after purchasing an additional 130,497 shares during the period. Finally, Integrated Advisors Network LLC boosted its holdings in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. Insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded up $12.85 during mid-day trading on Wednesday, hitting $425.69. 1,098,227 shares of the company were exchanged, compared to its average volume of 2,739,581. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a 50 day moving average of $414.16 and a 200-day moving average of $373.24. The stock has a market cap of $230.14 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 3.01 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the company posted $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Jefferies Financial Group reaffirmed a “hold” rating and issued a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. Argus increased their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. TD Cowen raised their target price on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Finally, HSBC lowered Amgen from a “buy” rating to a “hold” rating and cut their price target for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $387.93.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.